Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,473.47
(
0.37%
)
US TECH 100
28,612.40
(
0.11%
)
Dow Jones
50,579.70
(
0.58%
)
Brent Oil
101.17
(
0.00%
)
Bitcoin
77,229.95
(
0.28%
)
News Focus
News Focus
Post# of 257624
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: ghmm post# 149680

Sunday, 09/30/2012 7:44:41 PM

Sunday, September 30, 2012 7:44:41 PM

Post# of 257624
THLD - TH-302 data was presented at ESMO which showed a statsig 6mo PFS vs 3.6mo for gemcitabine alone, however the toxicities, especially at the 340mg level, are going to prove problematic.
http://biotechstrategyblog.com/2012/09/esmo-2012-th-302-pancreatic-cancer-survival-data-fails-to-impress.html/
Also, nice blurb at the end re: abraxane/CELGZ

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today